methyl 1-methyl-4-oxo-3-phenyl-4,5-dihydropyrrolo[1,2-a]quinoxalin-2-carboxylate | 716331-67-8

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二氮杂萘
• 英文名称: methyl 1-methyl-4-oxo-3-phenyl-4,5-dihydropyrrolo[1,2-a]quinoxalin-2-carboxylate
• 英文别名: 2-acetyl-1-methyl-3-phenyl-5H-pyrrolo[1,2-a]quinoxalin-4-one
• CAS: 716331-67-8
• 化学式: C₂₀H₁₆N₂O₂
• 分子量: 316.359
• InChiKey: FIVWMUXPSUACCV-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.3
• 重原子数：
  24
• 可旋转键数：
  2
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.1
• 拓扑面积：
  51.1
• 氢给体数：
  1
• 氢受体数：
  2

反应信息

• 作为产物：
  描述：

  3-(α-chlorobenzyl)-1,2-dihydroxyquinoxalin-2-one 在 氢氧化钾 作用下， 以 溶剂黄146 、 二甲基亚砜 为溶剂， 反应 4.0h， 生成 methyl 1-methyl-4-oxo-3-phenyl-4,5-dihydropyrrolo[1,2-a]quinoxalin-2-carboxylate
  参考文献：
  名称：

  Fused Polycyclic Nitrogen-Containing Heterocycles: VI. Pyrrolo[1,2-a]quinoxalines

  摘要：

  3-(beta-Chlorobenzyl)-1,2-dihydroquinoxalin-2-one reacts with anions derived from acetylacetone, benzoylacetone, dibenzoylmethane, malononitrile, ethyl acetoacetate, and ethyl cyanoacetate to give the corresponding 3-(beta-R,R'CH-benzyl)-1,2-dihydroquinoxatin-2-ones which undergo intramolecular cyclocondensation to functionally substituted pyrrolo[1,2-a]quinoxalines on heating in boiling acetic acid. The reaction of 3-(alpha-chloro-p-nitrobenzyl)-1,2-dihydroquinoxalin-2-one with acetylacetone anion directly leads to the corresponding pyrrolo[ 1,2-a]quinoxaline, without heating in acetic acid.

  DOI：

  10.1023/b:rujo.0000034919.73409.b3

文献信息

• PREVENTION AND TREATMENT OF INFLAMMATORY CONDITIONS
  申请人：GRI Bio, Inc.

  公开号：EP3229811B1

  公开（公告）日：2021-02-24
• [EN] PREVENTION AND TREATMENT OF INFLAMMATORY CONDITIONS<br/>[FR] PRÉVENTION ET TRAITEMENT DE PATHOLOGIES INFLAMMATOIRES
  申请人：GLYCOREGIMMUNE INC

  公开号：WO2016094226A1

  公开（公告）日：2016-06-16

  In accordance with some embodiments herein, methods and compositions for prevention and treatment of inflammatory conditions are provided. In some embodiments, compositions comprising NKT-2 activators, for example miltefosine are provided. In some embodiments, the compositions further comprise sulfatide and/or a RAR agonist. In some embodiments, the compositions comprise activators of Type II NKT cells, and/or inhibitors of Type I NKT cells.